Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting

PR Newswire
June 7, 2022 — 14:00 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: America biotech Covid-19 Economy healthcare japan manufacturing medicine Pandemic pharmaceutical stock exchange technology United States Website

Related News:

Lianlian Global Showcases Latest Innovations at Money 20/20 Asia 2024

April 25, 2024 — 23:52

INMOTION Debuts Innovational 2-in-1 Self-balancing Vehicle E20 at Global Sources HK Show 2024

April 25, 2024 — 23:50

Nature’s Miracle Announces Initial Shipments of the "MiracleTainer" Series Container Farm

April 25, 2024 — 23:30

Terra Drone, Unifly, and Aloft Technologies Launch UTM Development for AAM Targeting Global Markets

April 25, 2024 — 07:00

Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever

April 24, 2024 — 13:00

Zepp Health Corporation Files 2023 Annual Report on Form 20-F

April 23, 2024 — 20:20

TTC Announces Strategic Expansion into Western Australia with New Perth Office

April 23, 2024 — 04:00

Tantech Holdings Ltd Announces $2.1 Million Private Placement

April 23, 2024 — 03:58

Latham Adds Experienced M&A Partner in Tokyo

April 23, 2024 — 03:15